Document:

EXHIBIT 10.3

 

NEITHER THIS SECURITY NOR THE SECURITIES
AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH
EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

 

COMMON STOCK PURCHASE WARRANT

 

TPT GLOBAL TECH, INC.

 

Warrant Shares: 333,333

Date of Issuance: June 6, 2019 (“Issuance
Date”)

 

This COMMON STOCK PURCHASE
WARRANT (the “Warrant”) certifies that, for value received (in connection with the issuance of the $112,000.00
convertible promissory note to the Holder (as defined below) of even date) (the “Note”), JSJ Investments Inc.
(including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject
to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance hereof, to
purchase from TPT Global Tech, Inc., a Florida corporation (the “Company”), up to 333,333 shares of Common
Stock (as defined below) (the “Warrant Shares”) (whereby such number may be adjusted from time to time pursuant
to the terms and conditions of this Warrant) at the Exercise Price per share then in effect.

 

Capitalized terms used
in this Warrant shall have the meanings set forth in the Note unless otherwise defined in the body of this Warrant or in Section
12 below. For purposes of this Warrant, the term “Exercise Price” shall mean 70% multiplied by the Current Market
Price (as defined herein) (representing a discount of 30%), subject to adjustment as provided herein (including but not limited
to cashless exercise), and the term “Exercise Period” shall mean the period commencing on the Issuance
Date and ending on 5:00 p.m. eastern standard time on the five-year anniversary thereof. “Current Market Price”
means the average of the three (3) lowest Trading Prices (as defined below) for the Common Stock during the ten (10) Trading Day
period ending on the latest complete Trading Day prior to the date of the respective Exercise Notice, provided, however, that if
a registration statement registering the Warrant Shares (the “Registration Statement”) is declared effective
on or before September 6, 2019, then, while such Registration Statement is effective, the Current Market Price shall mean the lowest
daily volume weighted average price for the Common Stock during the ten (10) Trading Day period ending on the last complete Trading
Day prior to the date of the respective Exercise Notice.

 

1.       EXERCISE
OF WARRANT.

 

(a)       Mechanics
of Exercise. Subject to the terms and conditions hereof, the rights represented by this Warrant may be exercised in whole or
in part at any time or times during the Exercise Period by delivery of a written notice, in the form attached hereto as Exhibit
A (the “Exercise Notice”), of the Holder’s election to exercise this Warrant. The Holder shall not
be required to deliver the original Warrant in order to effect an exercise hereunder. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. On or before
the second Trading Day (the “Warrant Share Delivery Date”) following the date on which the Holder sent the Exercise
Notice to the Company or the Company’s transfer agent, and upon receipt by the Company of payment to the Company of an amount
equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which all or a portion of this Warrant
is being exercised (the “Aggregate

    	1 

    	 

    

Exercise Price” and together
with the Exercise Notice, the “Exercise Delivery Documents”) in cash or by wire transfer of immediately available
funds (or by cashless exercise, in which case there shall be no Aggregate Exercise Price provided), the Company shall (or direct
its transfer agent to) issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate,
registered in the Company’s share register in the name of the Holder or its designee, for the number of shares of Common
Stock to which the Holder is entitled pursuant to such exercise (or deliver such shares of Common Stock in electronic format if
requested by the Holder). Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes
to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective
of the date of delivery of the certificates evidencing such Warrant Shares. If this Warrant is submitted in connection with any
exercise and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant
Shares being acquired upon an exercise, then the Company shall as soon as practicable and in no event later than three Business
Days after any exercise and at its own expense, issue a new Warrant (in accordance with Section 6) representing the right to purchase
the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares
with respect to which this Warrant is exercised.

 

If the Company fails
to cause its transfer agent to transmit to the Holder the respective shares of Common Stock by the respective Warrant Share Delivery
Date, then the Holder will have the right to rescind such exercise in Holder’s sole discretion, and such failure shall be
deemed an event of default under the Note.

 

If the Market Price of
one share of Common Stock is greater than the Exercise Price, then, unless there is an effective non-stale registration statement
of the Company covering the Holder’s immediate resale of the Warrant Shares at prevailing market prices without any limitation,
the Holder may elect to receive Warrant Shares pursuant to a cashless exercise, in lieu of a cash exercise, equal to the value
of this Warrant determined in the manner described below (or of any portion thereof remaining unexercised) by surrender of this
Warrant and a Notice of Exercise, in which event the Company shall issue to Holder a number of Common Stock computed using the
following formula:

 

X = Y (A-B)

A

Where X =the number of Shares to be issued
to Holder.

		Y =	the number of Warrant Shares that the Holder elects to purchase under this Warrant (at the date
of such calculation).

A =       the
Market Price (at the date of such calculation).

B =       Exercise
Price (as adjusted to the date of such calculation).

 

(b)       No
Fractional Shares. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment
pursuant hereto. All Warrant Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes
of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would
result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise
entitled to such fraction a sum in cash equal to the product resulting from multiplying the then-current fair market value of a
Warrant Share by such fraction.

 

(c)       Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, to the extent that after giving effect to issuance of Warrant Shares upon exercise as set forth on
the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other persons acting as a group
together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of the Beneficial Ownership
Limitation, as defined below. For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by
the Holder and its Affiliates shall include the

    	2 

    	 

    

number of shares of Common Stock issuable
upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of
Common Stock which would be issuable upon (i) exercise of the remaining, non-exercised portion of this Warrant beneficially owned
by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or non-converted portion of any other
securities of the Company (including without limitation any other Common Stock Equivalents) subject to a limitation on conversion
or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set
forth in the preceding sentence, for purposes of this paragraph (d), beneficial ownership shall be calculated in accordance with
Section 13(d) of the Exchange Act, it being acknowledged by the Holder that the Company is not representing to the Holder that
such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules
required to be filed in accordance therewith. To the extent that the limitation contained in this paragraph applies, the determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any affiliates) and of
which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise
shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities
owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable, in each case subject to
the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.

 

For purposes of this
paragraph, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares
of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the
case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or its transfer
agent setting forth the number of shares of Common Stock outstanding. Upon the request of a Holder, the Company shall within two
Trading Days confirm to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including
this Warrant and the Note, by the Holder or its affiliates since the date as of which such number of outstanding shares of Common
Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant.
The limitations contained in this paragraph shall apply to a successor Holder of this Warrant.

 

2.       ADJUSTMENTS.
The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:

 

(a)       Distribution
of Assets. If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its
assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including without limitation any distribution
of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement
or other similar transaction, but not including a reverse split with respect to the Common Stock) (a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case:

 

(i)       any
Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders of
shares of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such record
date, to a price determined by multiplying such Exercise Price by a fraction (i) the numerator of which shall be the Closing Sale
Price of the shares of Common Stock on the Trading Day immediately preceding such record date minus the value of the Distribution
(as determined in good faith by the Company’s Board of Directors) applicable to one share of Common Stock, and (ii) the denominator
of which shall be the Closing Sale Price of the shares of Common Stock on the Trading Day immediately preceding such record date;
and

 

(ii)       the
number of Warrant Shares shall be increased to a number of shares equal to the number of shares of Common Stock obtainable immediately
prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to
receive the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding clause (i); provided,
however, that in the event that the Distribution is of shares of common stock of a company (other than the Company) whose common
stock is traded on a national securities exchange or a national automated quotation system (“Other Shares of

    	3 

    	 

    

Common Stock”), then
the Holder may elect to receive a warrant to purchase Other Shares of Common Stock in lieu of an increase in the number of Warrant
Shares, the terms of which shall be identical to those of this Warrant, except that such warrant shall be exercisable into the
number of shares of Other Shares of Common Stock that would have been payable to the Holder pursuant to the Distribution had the
Holder exercised this Warrant immediately prior to such record date and with an aggregate exercise price equal to the product
of the amount by which the exercise price of this Warrant was decreased with respect to the Distribution pursuant to the terms
of the immediately preceding clause (i) and the number of Warrant Shares calculated in accordance with the first part of this
clause (ii).

 

(iii)       For
the avoidance of doubt, no adjustment shall occur when shares of outstanding Common Stock are merged proportionally across all
stockholders to form a smaller number of outstanding shares of Common Stock.

 

(b)       Anti-Dilution
Adjustments to Exercise Price. If the Exercise Price decreases after the Issuance Date pursuant to the Exercise Price formula
as provided in this Warrant, or the Company or any Subsidiary thereof, as applicable, at any time while this Warrant is outstanding,
shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce
any offer, sale, grant or any option to purchase or other disposition) any Common Stock or securities entitling any person or entity
to acquire shares of Common Stock (upon conversion, exercise or otherwise) (including but not limited to under the Note), at an
effective price per share less than the then Exercise Price (such lower price, the “Base Share Price” and such
issuances collectively, a “Dilutive Issuance”) (if the holder of the Common Stock or Common Stock Equivalents
so issued shall at any time, whether by operation of purchase price adjustments, elimination of an applicable floor price for any
reason in the future (including but not limited to the passage of time or satisfaction of certain condition(s)), reset provisions,
floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued
in connection with such issuance, be entitled or potentially entitled to receive shares of Common Stock at an effective price per
share which is less than the Exercise Price at any time while such Common Stock or Common Stock Equivalents are in existence, such
issuance shall be deemed to have occurred for less than the Exercise Price on such date of the Dilutive Issuance (regardless of
whether the Common Stock or Common Stock Equivalents are (i) subsequently redeemed or retired by the Company after the date of
the Dilutive Issuance or (ii) actually converted or exercised at such Base Share Price), then the Exercise Price shall be reduced
at the option of the Holder and only reduced to equal the Base Share Price, and the number of Warrant Shares issuable hereunder
shall be increased such that the aggregate Exercise Price payable hereunder, after taking into account the decrease in the Exercise
Price, shall be equal to the aggregate Exercise Price prior to such adjustment (for the avoidance of doubt, the aggregate Exercise
Price prior to such adjustment is calculated as follows: the total number of Warrant Shares multiplied by the initial Exercise
Price in effect as of the Issuance Date). Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents
are issued, regardless of whether the Common Stock or Common Stock Equivalents are (i) subsequently redeemed or retired by the
Company after the date of the Dilutive Issuance or (ii) actually converted or exercised at such Base Share Price by the holder
thereof (for the avoidance of doubt, the Holder may utilize the Base Share Price even if the Company did not actually issue shares
of its common stock at the Base Share Price under the respective Common stock Equivalents). The Company shall notify the Holder
in writing, no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalents subject to this
Section 2(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and
other pricing terms (such notice the “Dilutive Issuance Notice”). For purposes of clarification, whether or
not the Company provides a Dilutive Issuance Notice pursuant to this Section 2(b), upon the occurrence of any Dilutive Issuance,
after the date of such Dilutive Issuance the Holder is entitled to receive a number of Warrant Shares based upon the Base Share
Price regardless of whether the Holder accurately refers to the Base Share Price in the Notice of Exercise.

 

3.       FUNDAMENTAL
TRANSACTIONS. If, at any time while this Warrant is outstanding, (i) the Company effects any merger of the Company with or
into another entity and the Company is not the surviving entity (such surviving entity, the “Successor Entity”),
(ii) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions, (iii) any
tender offer or exchange offer (whether by the Company or by another individual or entity, and approved by the Company) is completed
pursuant to which holders of Common Stock are permitted to tender or exchange their shares of Common Stock for other securities,
cash or property and the holders of at least 50% of the Common Stock accept such offer, or (iv) the Company effects any reclassification
of the Common Stock

    	4 

    	 

    

or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result
of a subdivision or combination of shares of Common Stock) (in any such case, a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive the number of shares of Common Stock
of the Successor Entity or of the Company and any additional consideration (the “Alternate Consideration”) receivable
upon or as a result of such reorganization, reclassification, merger, consolidation or disposition of assets by a holder of the
number of shares of Common Stock for which this Warrant is exercisable immediately prior to such event (disregarding any limitation
on exercise contained herein solely for the purpose of such determination). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions,
any Successor Entity in such Fundamental Transaction shall issue to the Holder a new warrant consistent with the foregoing provisions
and evidencing the Holder’s right to exercise such warrant into Alternate Consideration.

 

4.       NON-CIRCUMVENTION.
The Company covenants and agrees that it will not, by amendment of its certificate of incorporation, bylaws or through any reorganization,
transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good
faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder.
Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock
receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may be
necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable shares of Common
Stock upon the exercise of this Warrant, and (iii) shall, for so long as this Warrant is outstanding, have authorized and reserved,
free from preemptive rights, ten times the number of shares of Common Stock that is actually issuable upon full exercise of the
Warrant (based on the Exercise Price in effect from time to time, and without regard to any limitations on exercise).

 

5.       WARRANT
HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided herein, this Warrant, in and of itself, shall not
entitle the Holder to any voting rights or other rights as a stockholder of the Company. In addition, nothing contained in this
Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant
or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.

 

6.       REISSUANCE.

 

(a)       Lost,
Stolen or Mutilated Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company will, on such terms as to
indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof),
issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed.

 

(b)       Issuance
of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant
shall be of like tenor with this Warrant, and shall have an issuance date, as indicated on the face of such new Warrant which is
the same as the Issuance Date.

 

7.       TRANSFER.

 

(a)       Notice
of Transfer. The Holder agrees to give written notice to the Company before transferring this Warrant or transferring any Warrant
Shares of such Holder’s intention to do so, describing briefly the manner of any proposed transfer. Promptly upon receiving
such written notice, the Company shall present copies thereof to the Company’s counsel. If the proposed transfer may be effected
without registration or qualification (under any federal or

    	5 

    	 

    

state securities laws), the Company, as promptly
as practicable, shall notify the Holder thereof, whereupon the Holder shall be entitled to transfer this Warrant or to dispose
of Warrant Shares received upon the previous exercise of this Warrant, all in accordance with the terms of the notice delivered
by the Holder to the Company; provided, however, that an appropriate legend may be endorsed on this Warrant or the certificates
for such Warrant Shares respecting restrictions upon transfer thereof necessary or advisable in the opinion of counsel and satisfactory
to the Company to prevent further transfers which would be in violation of Section 5 of the Securities Act and applicable state
securities laws; and provided further that the prospective transferee or purchaser shall execute the Assignment of Warrant attached
hereto as Exhibit B and such other documents and make such representations, warranties, and agreements as may be required
solely to comply with the exemptions relied upon by the Company for the transfer or disposition of the Warrant or Warrant Shares.

 

(b)       If
the proposed transfer or disposition of this Warrant or such Warrant Shares described in the written notice given pursuant to this
Section 7 may not be effected without registration or qualification of this Warrant or such Warrant Shares, the Holder will limit
its activities in respect to such transfer or disposition as are permitted by law.

 

8.       NOTICES.
The Company shall provide the Holder with prompt written notice (i) immediately upon any adjustment of the Exercise Price,
setting forth in reasonable detail, the calculation of such adjustment and (ii) at least 20 days prior to the date on which the
Company closes its books or takes a record (A) with respect to any dividend or distribution upon the shares of Common Stock, (B)
with respect to any grants, issuances or sales of any stock or other securities directly or indirectly convertible into or exercisable
or exchangeable for shares of Common Stock or other property, pro rata to the holders of shares of Common Stock or (C) for determining
rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information
shall be made known to the public prior to or in conjunction with such notice being provided to the Holder.

 

9.       AMENDMENT
AND WAIVER. The terms of this Warrant may be amended or waived (either generally or in a particular instance and either retroactively
or prospectively) only with the written consent of the Company and the Holder.

 

10.       GOVERNING
LAW. This Warrant shall be governed by and construed in accordance with the laws of the State of Texas without regard to principles
of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Warrant
shall be brought only in the state courts of Texas or in the federal courts located in the State of Texas. The parties to this
Warrant hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert
any defense based on lack of jurisdiction or venue or based upon forum non conveniens. THE BORROWER HEREBY IRREVOCABLY
WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY. The prevailing party shall be entitled to recover
from the other party its reasonable attorney's fees and costs. In the event that any provision of this Warrant or any other agreement
delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall
be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or
rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability
of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process
being served in any suit, action or proceeding in connection with this Agreement or any other Transaction Document by mailing a
copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in
effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner
permitted by law.

 

11.       ACCEPTANCE.
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained
herein.

 

12.       CERTAIN
DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

    	6 

    	 

    

 

(a)       “Nasdaq”
means www.Nasdaq.com.

 

(b)       “Closing
Sale Price” means, for any security as of any date, (i) the last closing trade price for such security on the Principal
Market, as reported by Nasdaq, or, if the Principal Market begins to operate on an extended hours basis and does not designate
the closing trade price, then the last trade price of such security prior to 4:00 p.m., New York time, as reported by Nasdaq, or
(ii) if the foregoing does not apply, the last trade price of such security in the over-the-counter market for such security
as reported by Nasdaq, or (iii) if no last trade price is reported for such security by Nasdaq, the average of the bid and ask
prices of any market makers for such security as reported by the OTC Markets. If the Closing Sale Price cannot be calculated for
a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the
fair market value as mutually determined by the Company and the Holder. All such determinations to be appropriately adjusted for
any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

 

(c)       “Common
Stock” means the Company’s common stock, and any other class of securities into which such securities may hereafter
be reclassified or changed.

 

(d)       “Trading
Prices” means, for any security as of any date, the lesser of: (i) the lowest trade price on the OTC Pink, OTCQB or applicable
trading market as reported by a reliable reporting service (“Reporting Service”) designated by the Holder or, if the
OTC Pink is not the principal trading market for such security, the trading price of such security on the principal securities
exchange or trading market where such security is listed or traded or, if no trading price of such security is available in any
of the foregoing manners, the average of the trading prices of any market makers for such security that are listed in the “pink
sheets” by the National Quotation Bureau, Inc., or (ii) the closing bid price on the OTC Pink, OTCQB or applicable trading
market as reported by a Reporting Service designated by the Holder or, if the OTC Pink is not the principal trading market for
such security, the closing bid price of such security on the principal securities exchange or trading market where such security
is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the
closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation
Bureau, Inc.

 

(e)       “Common
Stock Equivalents” means any securities of the Company that would entitle the holder thereof to acquire at any time Common
Stock, including without limitation any debt, preferred stock, rights, options, warrants or other instrument that is at any time
convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

(f)       “Dilutive
Issuance” is any issuance of Common Stock or Common Stock Equivalents described in Section 2(b) above; provided, however,
that a Dilutive Issuance shall not include any Exempt Issuance.

 

(g)       “Exempt
Issuance” means the issuance of (i) shares of Common Stock or options to employees, officers, or directors of the Company
pursuant to any stock or option plan duly adopted by a majority of the non-employee members of the Board of Directors of the Company
or a majority of the members of a committee of non-employee directors established for such purpose, and (ii) shares of Common Stock
issued pursuant to real property leasing arrangement from a bank approved by the Board of Directors of the Company.

 

(h)       “Principal
Market” means the primary national securities exchange on which the Common Stock is then traded.

 

(i)       “Market
Price” means the highest traded price of the Common Stock during the ninety Trading Days prior to the date of the respective
Exercise Notice.

 

(j)       “Trading
Day” means (i) any day on which the Common Stock is listed or quoted and traded on its Principal Market, (ii) if the
Common Stock is not then listed or quoted and traded on any national securities exchange, then a day on which trading occurs on
any over-the-counter markets, or (iii) if trading does not occur on the over-the-counter markets, any Business Day.

 

* * * * * * * 

 

    	7 

    	 

    

IN WITNESS WHEREOF, the
Company has caused this Warrant to be duly executed as of the Issuance Date set forth above.

 

 

TPT GLOBAL TECH, INC.

 

 

 

Name: Stephen Thomas, III

Title: Chief Executive Officer

 

 

    	8 

    	 

    

EXHIBIT A

 

EXERCISE NOTICE

 

(To be executed by the registered holder to
exercise this Common Stock Purchase Warrant)

 

 

The
Undersigned holder hereby exercises the right to purchase _________________ of the shares of Common Stock (“Warrant
Shares”) of TPT Global Tech, Inc., a Florida corporation (the “Company”), evidenced by the attached copy of the
Common Stock Purchase Warrant (the “Warrant”). Capitalized terms used herein and not otherwise defined shall have
the respective meanings set forth in the Warrant.

 

		1.	Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be made
as (check one):

 

		☐	a cash exercise with respect to _________________ Warrant Shares; or
	 	☐	by cashless exercise pursuant to the Warrant.

 

 

		2.	Payment of Exercise Price. If cash exercise is selected above, the holder shall pay the
applicable Aggregate Exercise Price in the sum of $___________________ to the Company in accordance with the terms of the Warrant.

 

		3.	Delivery of Warrant Shares. The Company shall deliver to the holder __________________ Warrant
Shares in accordance with the terms of the Warrant.

 

 

 

Date: ________________________________

 

 

__________________________________

(Print Name of Registered Holder)

 

 

By: ___________________________________

Name: _________________________________

Title: __________________________________

 

    	 

    	 

    

EXHIBIT B

 

ASSIGNMENT OF WARRANT

 

(To be signed only upon authorized transfer
of the Warrant)

 

 

For
Value Received, the undersigned hereby sells, assigns, and transfers unto ____________________ the right to purchase _______________
shares of common stock of TPT Global Tech, Inc., to which the within Common Stock Purchase Warrant relates and appoints ____________________,
as attorney-in-fact, to transfer said right on the books of TPT Global Tech, Inc. with full power of substitution and re-substitution
in the premises. By accepting such transfer, the transferee has agreed to be bound in all respects by the terms and conditions
of the within Warrant.

 

 

 

Dated: __________________

 

 

_________________________________

(Signature) *

 

_________________________________

(Name)

 

_________________________________

(Address)

 

_________________________________

(Social Security or Tax Identification
No.)

 

 

 

* The signature on this Assignment of Warrant
must correspond to the name as written upon the face of the Common Stock Purchase Warrant in every particular without alteration
or enlargement or any change whatsoever. When signing on behalf of a corporation, partnership, trust or other entity, please indicate
your position(s) and title(s) with such entity.EXHIBIT 10.5 

SECURITIES PURCHASE AGREEMENT

This SECURITIES
PURCHASE AGREEMENT (this “Agreement”), dated as
of June 6, 2019, is entered into by and between TPT Global Tech, Inc., a Florida corporation (the “Company”), and EMA
Financial, LLC, a Delaware limited liability company (the “Purchaser”).

WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933,
as amended (the “Securities Act” or “1933 Act”), and Rule 506 promulgated thereunder by the United States
Securities and Exchange Commission (the “SEC”), the Company desires to issue and sell to the Purchaser, and the Purchaser
desires to purchase from the Company a 12% convertible note of the Company, in the form attached hereto as Exhibit A, in the principal
amount of $250,000.00 (together with any note(s) issued in replacement thereof or as interest thereon or otherwise with respect
thereto in accordance with the terms thereof, the “Note”), convertible into shares of common stock, $0.001 par value
per share (the “Common Stock”), of the Company, upon the terms and subject to the limitations and conditions set forth
in such Note.

NOW, THEREFORE,
IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:

		1.	Purchase and Sale of Note.

a)                 
Purchase of Note and Warrant. On the Closing Date (as defined below), the Company shall
issue and sell to the Purchaser, and the Purchaser agrees to purchase from the Company, the Note for an aggregate purchase price
of $235,000.00 (“Purchase Price”). Further, Company shall issue to Buyer as a commitment fee, a common stock purchase
warrant for the purchase of 1,000,000 shares of the Company’s common stock (the “Warrant”) pursuant to the terms
therein. The shares of the Company’s common stock into which the Note is convertible into and the Warrant is exercisable
into shall collectively be referred to herein as the “Conversion Shares”.

b)                 
Form of Payment. On the Closing Date (i) the Purchaser shall pay the Purchase Price
by wire transfer of immediately available funds, in accordance with the Company’s written instructions as provided in the
disbursement authorization dated June 6, 2019 and signed by the Company (the “Disbursement Authorization”), simultaneously
with delivery of the Note and Warrant, and (ii) the Company shall deliver such Note duly executed on behalf of the Company to the
Purchaser, simultaneously with delivery of such Purchase Price.

c)                 
Closing Date. Subject to the satisfaction (or written waiver) of the conditions thereto
set forth in Section 8 and Section 9 below, the closing of the transactions contemplated by this Agreement (the “Closing”)
shall occur on the first business day following the date hereof or such other mutually agreed upon time (the “Closing Date”)

2.     
Purchaser’s Representations and Warranties. The Purchaser represents and
warrants to the Company that:

    	1 

    	 

    

a)                 
Investment Purpose. Purchaser is acquiring the
Note and the Conversion Shares (collectively, the “Securities”) for its own account and not with a view towards, or
for resale in connection with, the public sale or distribution thereof in violation of applicable securities laws; provided, however,
by making the representations herein, Purchaser does not agree, or make any representation or warranty, to hold any of the Securities
for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant
to a registration statement or an exemption under the 1933 Act. The Purchaser is acquiring the Securities hereunder in the ordinary
course of its business. The Purchaser does not presently have any agreement or understanding, directly or indirectly, with any
person to distribute any of the Securities in violation of applicable securities laws.

b)                 
Accredited Investor Status. The Purchaser is an “accredited investor” as
that term is defined in Rule 501(a) of Regulation D (an “Accredited Investor”).

3.     
Representations and Warranties of the Company. Except as disclosed by the Company in
the publicly filed SEC Documents (as defined in this Agreement) the Company represents and warrants to the Purchaser, as of the
date hereof and the Closing Date, that:

a)                 
Organization and Qualification. The Company and each of its Subsidiaries (as defined
below), if any, is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which
it is incorporated, with full power and authority (corporate and other) to own, lease, use and operate its properties and to carry
on its business as and where now owned, leased, used, operated and conducted. The SEC Documents set forth a list of all of the
Subsidiaries of the Company and the jurisdiction in which each is incorporated The Company and each of its Subsidiaries is duly
qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which its ownership or use of
property or the nature of the business conducted by it makes such qualification necessary except where the failure to be so qualified
or in good standing would not have a Material Adverse Effect. “Material Adverse Effect” means any material adverse
effect on the business, operations, assets, financial condition or prospects of the Company or its Subsidiaries, if any, taken
as a whole, or on the transactions contemplated hereby or by the agreements or instruments to be entered into in connection herewith.
“Subsidiaries” means any corporation or other organization, whether incorporated or unincorporated, in which the Company
owns, directly or indirectly, any equity or other ownership interest.

b)                 
Authorization; Enforcement. (i) The Company has all requisite corporate power and authority
to enter into and perform this Agreement and the Note and to consummate the transactions contemplated hereby and thereby and to
issue the Securities, in accordance with the terms hereof and thereof, (ii) the execution and delivery of this Agreement and the
Note by the Company and the consummation by it of the transactions contemplated hereby and thereby (including without limitation,
the issuance of the Note and the issuance and reservation for issuance of the Conversion Shares issuable upon conversion and exercise
thereof) have been duly authorized by the Company’s Board of Directors and no further consent or authorization of the Company,
its Board of Directors, or its shareholders is required, (iii) this Agreement has been duly executed and delivered by the Company
by its authorized representative, and such authorized representative is the true and official representative with authority to
sign this Agreement and the

    	2 

    	 

    

other documents executed
in connection herewith and bind the Company accordingly, and (iv) this Agreement constitutes, and upon execution and delivery by
the Company of the Note and each of such instruments will constitute, a legal, valid and binding obligation of the Company enforceable
against the Company in accordance with its terms.

c)                 
Capitalization. As of the date hereof, the authorized capital stock of the Company,
and number of shares issued and outstanding, is as set forth in the Company’s most recent periodic report filed with the
SEC. Except as disclosed in the SEC Documents no shares are reserved for issuance pursuant to the Company’s stock option
plans. Except as disclosed in the SEC Documents no shares are reserved for issuance pursuant to securities exercisable for, or
convertible into or exchangeable for shares of Common Stock. All of such outstanding shares of capital stock are, or upon issuance
will be, duly authorized, validly issued, fully paid and non-assessable. No shares of capital stock of the Company are subject
to preemptive rights or any other similar rights of the shareholders of the Company or any liens or encumbrances imposed through
the actions or failure to act of the Company. As of the effective date of this Agreement, and except as disclosed in the SEC Documents,
(i) there are no outstanding options, warrants, scrip, rights to subscribe for, puts, calls, rights of first refusal, agreements,
understandings, claims or other commitments or rights of any character whatsoever relating to, or securities, notes or rights convertible
into or exchangeable for any shares of capital stock of the Company or any of its Subsidiaries, or arrangements by which the Company
or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries,
(ii) there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale
of any of its or their securities under the 1933 Act and (iii) there are no anti-dilution or price adjustment provisions contained
in any security issued by the Company (or in any agreement providing rights to security holders) that will be triggered by the
issuance of any of the Securities. The Company has furnished to the Purchaser true and correct copies of the Company’s Certificate
or Articles of Incorporation as in effect on the date hereof (“Formation Documents”), the Company’s By-laws,
as in effect on the date hereof (the “By-laws”), and the terms of all securities convertible into or exercisable for
Common Stock of the Company and the material rights of the holders thereof in respect thereto.

d)                 
Issuance of Shares. The Conversion Shares are duly authorized and reserved for issuance
and, upon conversion of the Note and/or exercise of the Warrant, as the case may be, in accordance with their respective terms,
will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances with respect to
the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Company and will
not impose personal liability upon the holder thereof.

e)                 
Acknowledgment of Dilution. The Company’s executive officers and directors understand
the nature of the Securities being sold hereby and recognize that the issuance of the Securities will have a potential dilutive
effect on the equity holdings of other holders of the Company’s equity or rights to receive equity of the Company.  The
Board of Directors of the Company has concluded, in its good faith business judgment that the issuance of the Securities is in
the best interests of the Company.  The Company specifically acknowledges that its obligation to issue the Conversion
Shares upon conversion of the Note and/or exercise of the Warrant is binding upon the Company and enforceable regardless of the
dilution such issuance may have on

    	3 

    	 

    

the ownership interests
of other stockholders of the Company or parties entitled to receive equity of the Company.

f)                  
No Conflicts. The execution, delivery and performance of this Agreement, and the Note
by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation,
the issuance and reservation for issuance of the Conversion Shares) will not (i) conflict with or result in a violation of any
provision of the Formation Documents or By-laws, or (ii) violate or conflict with, or result in a breach of any provision of, or
constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to others any
rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, patent, patent license or instrument
to which the Company or any of its Subsidiaries is a party and that is not filed as an SEC Document or other document filed with
the SEC, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities
laws and regulations and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable
to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound
or affected (except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would
not, individually or in the aggregate, have a Material Adverse Effect). Neither the Company nor any of its Subsidiaries is in violation
of its Formation Documents, By-laws or other organizational documents and neither the Company nor any of its Subsidiaries is in
default (and no event has occurred which with notice or lapse of time or both could put the Company or any of its Subsidiaries
in default) under, and neither the Company nor any of its Subsidiaries has taken any action or failed to take any action that would
give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to
which the Company or any of its Subsidiaries is a party or by which any property or assets of the Company or any of its Subsidiaries
is bound or affected, except for possible defaults as would not, individually or in the aggregate, have a Material Adverse Effect.
The businesses of the Company and its Subsidiaries, if any, are not being conducted, and shall not be conducted so long as the
Purchaser owns any of the Securities, in violation of any law, ordinance or regulation of any governmental entity. Except as specifically
contemplated by this Agreement and as required under the 1933 Act and any applicable state securities laws, the Company is not
required to obtain any consent, authorization or order of, or make any filing or registration with, any court, governmental agency,
regulatory agency, self-regulatory organization or stock market or any third party in order for it to execute, deliver or perform
any of its obligations under this Agreement and the Note in accordance with the terms hereof or thereof or to issue and sell the
Securities in accordance with the terms hereof and thereof and to issue the Conversion Shares. All consents, authorizations, orders,
filings and registrations which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected
on or prior to the date hereof. The Company is not in violation of the listing requirements of the Principal Market (as defined
in this Agreement) and does not reasonably anticipate that the Common Stock will be delisted by the Principal Market in the foreseeable
future. The Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.

g)                 
SEC Documents; Financial Statements. The Company has filed all reports, schedules,
forms, statements and other documents required to be filed by it with the SEC (all of

    	4 

    	 

    

the foregoing filed prior
to the date hereof and all exhibits included therein and financial statements and schedules thereto and documents (other than exhibits
to such documents) incorporated by reference therein, being hereinafter referred to herein as the “SEC Documents”).
Upon written request the Company will deliver to the Purchaser true and complete copies of the SEC Documents, except for such exhibits
and incorporated documents. As of their respective dates, the SEC Documents complied in all material respects with the requirements
of the Securities Exchange Act of 1934, as amended (“1934 Act” or “Exchange Act”), and none of the SEC
Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which
they were made, not misleading. None of the statements made in any such SEC Documents is, or has been, required to be amended or
updated under applicable law (except for such statements as have been amended or updated in subsequent filings prior the date hereof).
As of their respective dates, the financial statements of the Company included in the SEC Documents complied as to form in all
material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto.
Such financial statements have been prepared in accordance with United States generally accepted accounting principles, consistently
applied, during the periods involved and fairly present in all material respects the consolidated financial position of the Company
and its consolidated Subsidiaries as of the dates thereof and the consolidated results of their operations and cash flows for the
periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). Except as set forth in
the financial statements of the Company included in the SEC Documents, the Company has no liabilities, contingent or otherwise,
other than (i) liabilities incurred in the ordinary course of business, and (ii) obligations under contracts and commitments incurred
in the ordinary course of business and not required under generally accepted accounting principles to be reflected in such financial
statements, which, individually or in the aggregate, are not material to the financial condition or operating results of the Company.
The Company is subject to the reporting requirements of the 1934 Act.

h)                 
Absence of Certain Changes. Since December 31, 2018, there has been no material adverse
change and no material adverse development in the assets, liabilities, business, properties, operations, financial condition, results
of operations, prospects or 1934 Act reporting status of the Company or any of its Subsidiaries.

i)                  
Absence of Litigation. Except as disclosed in the SEC Documents, tthere is no action,
suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization
or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened against or affecting the Company or
any of its Subsidiaries, or their officers or directors in their capacity as such, that could have a Material Adverse Effect. The
public filings contain a complete list and summary description of any pending or, to the knowledge of the Company, threatened proceeding
against or affecting the Company or any of its Subsidiaries, without regard to whether it would have a Material Adverse Effect.
The Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.

j)                  
Patents, Copyrights, etc. The Company and each of its Subsidiaries owns or possesses
the requisite licenses or rights to use all patents, patent applications, patent rights,

    	5 

    	 

    

inventions, know-how, trade
secrets, trademarks, trademark applications, service marks, service names, trade names and copyrights (“Intellectual Property”)
necessary to enable it to conduct its business as now operated (and, as presently contemplated to be operated in the future); there
is no claim or action by any person pertaining to, or proceeding pending, or to the Company’s knowledge threatened, which
challenges the right of the Company or of a Subsidiary with respect to any Intellectual Property necessary to enable it to conduct
its business as now operated (and, as presently contemplated to be operated in the future); to the best of the Company’s
knowledge, the Company’s or its Subsidiaries’ current and intended products, services and processes do not infringe
on any Intellectual Property or other rights held by any person and/or entity; and the Company is unaware of any facts or circumstances
which might give rise to any of the foregoing. The Company and each of its Subsidiaries have taken reasonable security measures
to protect the secrecy, confidentiality and value of their Intellectual Property.

k)                 
No Materially Adverse Contracts, Etc. Neither the Company nor any of its Subsidiaries
is subject to any charter, corporate or other legal restriction, or any judgment, decree, order, rule or regulation which in the
judgment of the Company’s officers has or is expected in the future to have a Material Adverse Effect. Neither the Company
nor any of its Subsidiaries is a party to any contract or agreement which in the judgment of the Company’s officers has or
is expected to have a Material Adverse Effect.

l)                  
Disclosure. No event or circumstance has occurred or exists with respect to the Company
or any of its Subsidiaries or its or their business, properties, prospects, operations or financial conditions, which, under applicable
law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced
or disclosed.

m)              
Brokers. Except with respect to Network 1 Financial Securities Inc., a registered broker-dealer
(CRD#: 13577), the Company hereby represents and warrants that it has not hired, retained or dealt with any broker, finder, consultant,
person, firm or corporation (“Broker”) in connection with the negotiation, execution or delivery of this Agreement
or the transactions contemplated hereunder. The Company covenants and agrees that should any claim be made against Purchaser for
any commission or other compensation by the Broker, based upon the Company’s engagement of such person in connection with
this transaction, the Company shall indemnify, defend and hold Purchaser harmless from and against any and all damages, expenses
(including attorneys’ fees and disbursements) and liability arising from such claim. The Company shall pay the commission
of the Broker, to the attention of the Broker, pursuant to their separate agreement(s) between the Company and the Broker.

n)                 
Permits; Compliance. The Company and each of its Subsidiaries is in possession of all
franchises, grants, authorizations, licenses, permits, easements, variances, exemptions, consents, certificates, approvals and
orders necessary to own, lease and operate its properties and to carry on its business as it is now being conducted (collectively,
the “Company Permits”), and there is no action pending or, to the knowledge of the Company, threatened regarding suspension
or cancellation of any of the Company Permits. Neither the Company nor any of its Subsidiaries is in conflict with, or in default
or violation of, any of the Company Permits, except for any such conflicts, defaults or violations which, individually or in the
aggregate, would not reasonably be expected to have a Material Adverse Effect. Since December 31, 2018, neither

    	6 

    	 

    

the Company nor any of
its Subsidiaries has received any notification with respect to possible conflicts, defaults or violations of applicable laws, except
for notices relating to possible conflicts, defaults or violations, which conflicts, defaults or violations would not have a Material
Adverse Effect.

o)                       
Insurance. The Company and its Subsidiaries are insured by insurers of recognized financial
responsibility against such losses and risks and in such coverage, amounts as are prudent and customary in the businesses in which
the Company is engaged, including, but not limited to, directors and officer’s insurance coverage with coverage amounts that
are at least equal to the aggregate Purchase Price. Neither the Company nor any Subsidiary has any reason to believe that it will
not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business without a significant increase in cost.

p)                 
No “Shell”. As of the date of this Agreement the Company is an operating
company and, either (i) is not or has never been a “shell issuer” as defined in Rule 144(i)(2) or (ii) at least 12
months have passed since the Company filed Form 10 Type information indicating it is not a “shell issuer” (and supporting
the claim that it is no longer a shell company), filed all required reports for at least twelve consecutive months after the filing
of the respective Form 10 information, and has therefore complied with Rule 144(i)(2).

 

q)                 
Bad Actor. No officer or director of the Company would be disqualified under Rule 506(d)
of the Securities Act as amended on the basis of being a “bad actor”. 

 

r)                  
Acknowledgement Regarding Purchaser’s Trading Activity. Notwithstanding anything
in this Agreement or elsewhere to the contrary it is understood and acknowledged by the Company that: (i) the Purchaser has not
been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, securities of the Company,
or “derivative” securities based on securities issued by the Company or to hold the Securities for any specified term;
(ii) each Purchaser shall not be deemed to have any affiliation with or control over any arm’s length counter-party in any
“derivative” transaction. 

 

s)                 
Sarbanes-Oxley Act. The Company and each Subsidiary is in material compliance with
all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and all applicable rules
and regulations promulgated by the SEC thereunder that are effective as of the date hereof. 

 

		4.	COVENANTS.

a)                 
Best Efforts. The parties shall use their best efforts to satisfy timely each of the
conditions described in Section 6 and 7 of this Agreement.

    	7 

    	 

    

b)                 
Form D; Blue Sky Laws. The Company agrees when applicable to timely file a Form D with
respect to the Securities as required under Regulation D and to provide a copy thereof to the Purchaser promptly after such filing.
The Company shall, on or before the Closing Date, take such action as the Company shall reasonably determine is necessary to qualify
the Securities for sale to the Purchaser at the applicable closing pursuant to this Agreement under applicable securities or “blue
sky” laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence
of any such action so taken to the Purchaser on or prior to the Closing Date.

c)                 
Use of Proceeds. The Company shall use
the proceeds from the sale of the Securities for general corporate purposes, marketing and sales, product development, key personnel
recruiting and business development purposes, and
shall not, directly or indirectly, use such proceeds for the repayment of any debt issued in corporate finance transactions or
any loan to or investment in any other corporation, partnership, enterprise or other person (except in connection with the Company’s
currently existing operations).

d)                 
Financial Information. Upon written request of the Purchaser, the Company agrees to
within (3) three days of the written request send or make available the following reports filed with the SEC or OTC Markets Group
to the Purchaser: a copy of its Annual Report and its Quarterly Reports and any Supplemental Reports; (ii) copies of all press
releases issued by the Company or any of its Subsidiaries; and (iii) copies of any notices or other information the Company makes
available or gives to such shareholders. Notwithstanding the foregoing, the Company shall not disclose any material nonpublic information
to the Purchaser without its consent unless such information is disclosed to the public prior to or promptly following such disclosure
to the Purchaser.

e)                 
Listing. The Company will obtain and, so long as the Purchaser owns any of the Securities,
maintain the listing and trading of its Common Stock on the Principal Market, and will comply in all respects with the Company’s
reporting, filing and other obligations under the bylaws or rules of the Financial Industry Regulatory Authority (“FINRA”)
and such exchanges, as applicable. The Company shall promptly provide to the Purchaser copies of any notices it receives from the
SEC, OTC Markets Group and any other exchanges or quotation systems on which the Common Stock is then listed regarding the continued
eligibility of the Common Stock for listing on such exchanges and quotation systems, provided that it shall not provide any notices
constituting material nonpublic information. If at any time while the Note is outstanding the Company fails to maintain the listing
and trading and of its Common Stock, or fails in any way to comply with the Company’s reporting/ filing obligations such
failure(s) will result in liquidated damages of fifteen thousand dollars ($15,000), being immediately due and payable to Holder
at its election in the form of cash payment or addition to the balance of the Note.

f)                  
Corporate Existence. So long as the Purchaser beneficially owns any Securities, the
Company shall maintain its corporate existence and shall not sell all or substantially all of the Company’s assets, except
in the event of a merger or consolidation or sale of all or substantially all of the Company’s assets, where the surviving
or successor entity in such transaction (i) assumes the Company’s obligations hereunder and under the agreements

    	8 

    	 

    

and instruments entered
into in connection herewith and (ii) is a publicly traded corporation whose Common Stock is listed for trading on Principal Market.

g)                 
No Integration. The Company shall not make any offers or sales of any security (other
than the Securities) under circumstances that would require registration of the Securities being offered or sold hereunder under
the 1933 Act or cause the offering of the Securities to be integrated with any other offering of securities by the Company for
the purpose of any stockholder approval provision applicable to the Company or its securities.

h)                 
Securities Laws Disclosure; Publicity. The Company shall comply with applicable securities
laws by filing a Current Report on Form 8-K, within four (4) Trading Days following the date hereof, disclosing all the material
terms of the transactions contemplated hereby.

 

i)                  
Non-Public Information. Except with respect to the material terms and conditions of
the transactions contemplated by this Agreement, the Company covenants and agrees that neither it nor any other person acting on
its behalf will provide the Purchaser or its agents or counsel with any information that the Company believes constitutes material
non-public information, unless prior thereto the Purchaser shall have executed a written agreement regarding the confidentiality
and use of such information. The Company understands and confirms that the Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.

 

j)                  
Subsidiaries. So long as the Note remains outstanding, the Company shall not transfer
any assets or rights to any of its subsidiaries or permit any of its subsidiaries to engage in any significant business or operations,
whether such subsidiaries are currently existing or hereafter created.

 

k)                 
Insurance. So long as the Note remains outstanding, the Company and its Subsidiaries
shall maintain in full force and effect insurance reasonably believed by the Company to be adequate coverage (a) on all assets
and activities, covering property loss or damage and loss of income by fire or other hazards or casualty, and (b) against all liabilities,
claims and risks for which it is customary for companies similarly situated to the Company to insure, including without limitation
applicable product liability insurance, required workmen’s compensation insurance, and other insurance covering injury or
damage to persons or property, but excluding directors and officers insurance coverage. The Company shall promptly furnish or cause
to be furnished evidence of such insurance to the Purchaser, in form and substance reasonably satisfactory to the Purchaser

 

l)                  
ROFR. At any time while the Note is outstanding, the Company desires to borrow funds,
raise additional capital and/or issue additional promissory notes convertible into shares of securities of the Company (a “Prospective
Financing”), the Purchaser shall have the right of first refusal to participate in the Prospective Financing (if the Company
has previously granted a right of first refusal to any other party prior to the date of this Agreement and such rights are still
in effect at the time of the Prospective Financing, then the Purchaser’s right of first refusal hereunder shall be secondary
to such other party), and the Company shall provide written notice

    	9 

    	 

    

containing the terms of such Prospective
Financing (the “ROFR Notice”) to the Purchaser prior to effectuating any such transaction.
 The ROFR Notice shall specify all of the key terms of the Prospective Financing, including, but not limited to, the proposed
investment amount, the proposed rate of interest, the proposed conversion price, the proposed term of the investment, the type
and number of securities to be sold and any and all other relevant terms, each as applicable. Upon Purchaser’s receipt of
the ROFR Notice, Purchaser shall have the exclusive right to participate in such Prospective Financing(s), upon the terms specified
in the ROFR Notice, by sending written notice to the Company within five (5) business days after Purchaser’s receipt of the
ROFR Notice. In the event Purchaser fails to exercise its right of first refusal with respect to an ROFR Notice within the time
set forth above, Purchaser shall be deemed to have waived its right of first refusal with respect to such Prospective Financing,
provided that it shall retain such right with respect to any future Prospective Financing. Notwithstanding anything contained herein,
the Company shall not furnish any material non-public information concerning the Company without the Purchaser’s prior written
consent, and shall initially only indicate to the Purchaser that the Company contemplates a financing. Notwithstanding anything
contained herein, in no event shall the Purchaser be entitled to purchase any securities which would cause the sum of (1) the number
of shares of Common Stock beneficially owned by the Purchaser and its affiliates (other than shares of Common Stock which may be
deemed beneficially owned through the ownership of the unconverted portion of the Note or the unexercised or unconverted portion
of any other security of the Company subject to a limitation on conversion or exercise analogous to the limitations contained herein)
and (2) the number of shares of directly or indirectly purchasable under this Section, to exceed 4.99% of the outstanding shares
of Common Stock (or 9.99% of the total issued Common Stock of the Company if specified by Purchaser and accompanied with applicable
documentation such as any Amendment made to this Agreement or the Note).

 

m)              
Future Financings: From the date hereof until such time as the Purchaser no longer
holds any of the Securities, in the event the Company issues or sells any shares of Common Stock or securities directly or indirectly
convertible into or exercisable for Common Stock (“Common Stock Equivalents”) or amends the transaction documents relating
to any sale or issuance of Common Stock or Common Stock Equivalents, and the Purchaser reasonably believes that the terms and conditions
thereunder are more favorable to such investors as the terms and conditions granted under this Agreement, Note or any document
provided by the Purchaser to the Company relating to any sale or issuance of Common Stock (the “Transaction Documents”),
upon notice to the Company by such Purchaser, the Transaction Documents shall be deemed automatically amended so as to give the
Purchaser the benefit of such more favorable terms or conditions. Promptly following a request to the Company, the Company shall
provide Purchaser with all executed transaction documents relating to any such sale or issue of Common Stock or Common Stock Equivalents.
Company shall deliver acknowledgment of such automatic amendment to the Transaction Documents to Purchaser in form and substance
reasonably satisfactory to the Purchaser (the “Acknowledgment”) within three (3) business days of Company’s receipt
of request from Purchaser (the “Deadline”), provided that Company’s failure to timely provide the Acknowledgement
shall not affect the automatic amendments contemplated hereby. If the Acknowledgement is not delivered by the Deadline, Company
shall pay to the Purchaser $1,000.00 per day in cash, for each day beyond the Deadline that the Company fails to

    	10 

    	 

    

deliver such Acknowledgement such cash
amount shall be paid to Holder by the first day of the month following the month in which it has accrued or, at the option of the
Holder, shall be added to the principal amount of the Note, in which event interest shall accrue thereon in accordance with the
terms of the Note and such additional principal amount shall be convertible into Common Stock in accordance with the terms of the
Note.

 

n)                 
Piggyback Registration Rights. Borrower shall include all shares issuable upon conversion
of the Note on: (i) the next registration statement and Regulation A offering statement Borrower files with the SEC; (ii) the subsequent
registration statement if such previous registration statement is withdrawn, (iii) the subsequent Regulation A offering statement
if such previous Regulation A offering statement is withdrawn, (iv) any amendment to any registration statement previously filed
but not effective as of the Issue Date (as defined in the Note), and (v) any amendment to any Regulation A offering statement previously
filed but not qualified as of the Issue Date. Failure to do so will result in liquidated damages of fifty percent (50%) of the
outstanding principal amount of the Note, but not less than twenty-five thousand dollars ($25,000), being immediately due and payable
to Holder at its election in the form of cash payment or addition to the balance of the Note.

 

o)                 
Subsequent Financings. Notwithstanding anything contained herein, if at any time while
this Note is outstanding the Company enters into any capital raising transaction, including without limitation an equity line transaction,
a loan transaction or the sale of shares of Common Stock or securities convertible into or exercisable or exchangeable for Common
Stock, whether or not permitted under the Transaction Documents, which results in proceeds of $2,500,000.00 or more (“Subsequent
Financing”), then following the closing of each such Subsequent Financing the Holder in its sole and absolute discretion
may compel the Company to redeem up to the entire outstanding balance of the Note from the gross proceeds therefrom (“Redemption
Amount”), provided however (a) if the Holder is holding other convertible notes similar to this Note whether issued prior
or after the Issue Date of this Note (collectively with this Note, the “Notes”), the Redemption Amount may be applied
to redeem any or all of the Notes specified by the Holder, (b) the Holder shall be notified in writing of the closing of each such
Subsequent Financing within one (1) day following such closing, and (c) the Holder may elect not to exercise its right to such
redemption in whole or in part, in which case the Company may not redeem any Notes in connection with such Subsequent Financing
to the extent so rejected (for clarification, if the holder elects to reject any redemption in any instance, such rejection shall
not affect the Holder’s redemption rights hereunder in the future). Further, in the event that the Holder demands redemption
of a portion or the full balance of the Note within the first six (6) months from Note’s Issue Date, such Redemption Amount
shall subject to then then applicable Prepayment Factor, as defined in the Note shall be applied). To the extent the Company is
obligated to redeem any portion of the Notes pursuant to this Section but fails to do so, such default shall constitute an Event
of Default under all the Notes.

 

p)                 
[Intentionally Omitted]. 

 

5.     
Transfer Agent Instructions. Upon receipt of a duly executed Notice of Conversion,
the Company shall issue irrevocable instructions to its transfer agent to issue certificates,

    	11 

    	 

    

registered in the name
of the Purchaser or its nominee, for the Conversion Shares in such amounts as specified from time to time by the Purchaser to the
Company upon conversion of the Note, or any part thereof, in accordance with the terms thereof (the “Irrevocable Transfer
Agent Instructions”). In the event that the Company proposes to replace its transfer agent, the Company shall provide, prior
to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered
pursuant to this Agreement and the Securities (including but not limited to the provision to irrevocably reserve shares of Common
Stock in the Reserved Amount (as defined in the Note)) signed by the successor transfer agent (to the Company) and the Company.
Prior to registration of the Conversion Shares under the 1933 Act or the date on which the Conversion Shares may be sold pursuant
to Rule 144 without any restriction as to the number of Securities as of a particular date that can then be immediately sold, all
such certificates shall bear the restrictive legend specified in Section 2(g) of this Agreement. The Company warrants that: (i)
no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5, and stop transfer instructions
to give effect to hereof (in the case of the Conversion Shares, prior to registration of the Conversion Shares under the 1933 Act
or the date on which the Conversion Shares may be sold pursuant to Rule 144 without any restriction as to the number of Securities
as of a particular date that can then be immediately sold), will be given by the Company to its transfer agent and that the Securities
shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement
and the Note; (ii) it will not direct its transfer agent not to transfer or delay, impair, and/or hinder its transfer agent in
transferring (or issuing)(electronically or in certificated form) any certificate for Conversion Shares to be issued to the Purchaser
upon conversion of or otherwise pursuant to the Note and/or Warrant as and when required by the Note, Warrant, and/or this Agreement;
and (iii) it will not fail to remove (or direct its transfer agent not to remove or impair, delay, and/or hinder its transfer agent
from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any certificate for
any Conversion Shares issued to the Purchaser upon conversion of or otherwise pursuant to the Note and/or Warrant as and when required
by the Note, Warrant, and/or this Agreement. Nothing in this Section shall affect in any way the Purchaser’s obligations
and agreement set forth in Section 2(g) hereof to comply with all applicable prospectus delivery requirements, if any, upon re-sale
of the Securities. If the Purchaser provides the Company with (i) an opinion of counsel in form, substance and scope customary
for opinions in comparable transactions, to the effect that a public sale or transfer of such Securities may be made without registration
under the 1933 Act and such sale or transfer is effected or (ii) the Purchaser provides reasonable assurances that the Securities
can be sold pursuant to Rule 144, the Company shall permit the transfer, and, in the case of the Conversion Shares, promptly instruct
its transfer agent to issue one or more certificates, free from restrictive legend, in such name and in such denominations as specified
by the Purchaser. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the
Purchaser, by vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the Company acknowledges that
the remedy at law for a breach of its obligations under this Section 5 may be inadequate and agrees, in the event of a breach or
threatened breach by the Company of the provisions of this Section, that the Purchaser shall be entitled, in addition to all other
available remedies, to an injunction restraining any breach and requiring immediate

    	12 

    	 

    

transfer, without the
necessity of showing economic loss and without any bond or other security being required.

6.     
Injunction Posting of Bond.  In the event the Purchaser shall elect to convert
the Note or any parts thereof, the Company may not refuse conversion or exercise based on any claim that Purchaser or anyone associated
or affiliated with Purchaser has been engaged in any violation of law, or for any other reason. In connection with any injunction
sought or attempted by the Company, the Company shall be required to post a bond at least equal to the greater of either: (i) the
outstanding principal amount of the Note; and (ii) the market value of the Conversion Shares sought to be converted, exercised
or issued, based on the sale price per share of Common Stock on the principal market on which it is traded.

7.     
Delivery of Unlegended Shares.

a)                 
Within one (1) business day (such first business day being the “Unlegended Shares
Delivery Date”) after the business day on which the Company has received (i) a notice that Conversion Shares, or any
other Common Stock held by the Purchaser has been sold pursuant to a registration statement or Rule 144 under the 1933 Act, (ii)
a representation that the prospectus delivery requirements, or the requirements of Rule 144, as applicable and if required, have
been satisfied, (iii) the original share certificates representing the shares of Common Stock that have been sold, and (iv) in
the case of sales under Rule 144, customary representation letters of the Purchaser and, if required, Purchaser’s broker
regarding compliance with the requirements of Rule 144, the Company at its expense, (y) shall deliver, and shall cause legal counsel
selected by the Purchaser to deliver to its transfer agent (with copies to Purchaser) an appropriate instruction and opinion of
such counsel, directing the delivery of shares of Common Stock without any legends including the legend set forth in Section 4(h)
above (the “Unlegended Shares”); and (z) cause the transmission of the certificates representing the Unlegended
Shares together with a legended certificate representing the balance of the submitted Common Stock certificate, if any, to the
Purchaser at the address specified in the notice of sale, via express courier, by electronic transfer or otherwise on or before
the Unlegended Shares Delivery Date.

b)                 
The Company understands that a delay in the delivery of the Unlegended Shares later than the
Unlegended Shares Delivery Date could result in economic loss to the Purchaser. As compensation to Purchaser for such loss, the
Company agrees to pay late payment fees (as liquidated damages and not as a penalty) to the Purchaser for late delivery of Unlegended
Shares in the amount of $250.00 per business day after the Unlegended Shares Delivery Date. If during any three hundred and sixty
(360) day period, the Company fails to deliver Unlegended Shares as required by this Section for an aggregate of thirty (30) days,
then Purchaser or assignee holding Securities subject to such default may, at its option, require the Company to redeem all or
any portion of the shares subject to such default at a price per share equal to the greater of (i) 200% of the most recent closing
price of the Common Stock or (ii) the parity value of the Default Sum to be paid (as defined in Section 3.16 of the Note) (“Unlegended
Redemption Amount”). The Company shall pay any payments incurred under this Section in immediately available funds upon
demand.

    	13 

    	 

    

8.     
Conditions to the Company’s Obligation to Sell. The obligation of the Company
hereunder to issue and sell the Note to the Purchaser at the Closing is subject to the satisfaction, at or before the Closing Date
of each of the following conditions provided that these conditions are for the Company’s sole benefit and may be waived by
the Company at any time in its sole discretion:

a)                 
The Purchaser shall have executed this Agreement and delivered the same to the Company.

b)                 
The Purchaser shall have delivered the Purchase Price to the Company.

c)                 
The representations and warranties of the Purchaser shall be true and correct in all material
respects as of the date when made and as of the Closing Date as though made at that time (except for representations and warranties
that speak as of a specific date), and the Purchaser shall have performed, satisfied and complied in all material respects with
the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Purchaser
at or prior to the Closing Date.

d)                 
No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall
have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any
self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of the
transactions contemplated by this Agreement.

9.     
Conditions to The Purchaser’s Obligation to Purchase. The obligation of the Purchaser
hereunder to purchase the Note at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following
conditions, provided that these conditions are for the Purchaser’s sole benefit and may be waived by the Purchaser at any
time in its sole discretion:

a)                 
The Company shall have executed this Agreement and delivered the same to the Purchaser.

b)                 
The Company shall have delivered to the Purchaser the duly executed Note (in such denominations
as the Purchaser shall request) in accordance with Section 1 above.

c)                 
The Irrevocable Transfer Agent Instructions, in form and substance satisfactory to the Purchaser,
shall have been delivered to and acknowledged in writing by the Company’s Transfer Agent (a copy of which written acknowledgment
shall be provided to Purchaser prior to Closing).

d)                 
The representations and warranties of the Company shall be true and correct in all material
respects as of the date when made and as of the Closing Date as though made at such time (except for representations and warranties
that speak as of a specific date) and the Company shall have performed, satisfied and complied in all material respects with the
covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or
prior to the Closing Date. The Purchaser shall have

    	14 

    	 

    

received a certificate
or certificates reasonably requested by the Purchaser including, but not limited to certificates with respect to the Company’s
Formation Documents, By-laws, and Board of Directors’ resolutions relating to the transactions contemplated hereby.

e)                 
No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall
have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any
self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of the
transactions contemplated by this Agreement.

f)                  
No event shall have occurred which could reasonably be expected to have a Material Adverse
Effect on the Company including but not limited to a change in the 1934 Act reporting status of the Company or the failure of the
Company to be timely in its 1934 Act reporting obligations.

g)                 
The Conversion Shares shall have been authorized for quotation on the Principal Market and
trading of the Common Stock on the Principal Market shall not have been suspended by the SEC or the Principal Market.

		10.	Governing Law; Miscellaneous.

a)                 
Governing Law. This Agreement shall be governed
by and construed in accordance with the laws of the State of Delaware without regard to principles of conflicts of laws thereof
or any other State.  Any action brought by any party against any other party hereto concerning the transactions contemplated
by this Agreement shall be brought only in the state courts of New York or in the federal courts located in the state and county
of New York.  The parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action
instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens.  The
parties executing this Agreement and other agreements referred to herein or delivered in connection herewith on behalf of the Company
agree to submit to the in personam jurisdiction of such courts and hereby irrevocably waive trial by jury.  The prevailing
party shall be entitled to recover from the other party its reasonable attorney’s fees and costs.  In the event
that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable under
any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith
and shall be deemed modified to conform with such statute or rule of law.  Any such provision which may prove invalid
or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.  Each
party hereto hereby irrevocably waives personal service of process and consents to process being served in any suit, action or
proceeding in connection with this Agreement or any other transaction document contemplated hereby by mailing a copy thereof via
registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices
to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

    	15 

    	 

    

b)                 
Removal of Restrictive Legends.  In the event that
Purchaser has any shares of the Company’s Common Stock bearing any restrictive legends, and Purchaser, through its counsel
or other representatives, submits to the Transfer Agent any such shares for the removal of the restrictive legends thereon in connection
with a sale of such shares pursuant to any exemption to the registration requirements under the Securities Act, and the
Company and or its counsel refuses or fails for any reason (except to the extent that such refusal or failure is based solely on
applicable law that would prevent the removal of such restrictive legends) to render an opinion of counsel or any other documents
or certificates required for the removal of the restrictive legends, then the Company hereby agrees and acknowledges that the Purchaser
is hereby irrevocably and expressly authorized to have counsel to the Purchaser render any and all opinions and other certificates
or instruments which may be required for purposes of removing such restrictive legends, and the Company hereby irrevocably authorizes
and directs the Transfer Agent to, without any further confirmation or instructions from the Company, issue any such shares without
restrictive legends as instructed by the Purchaser, and surrender to a common carrier for overnight delivery to the address as
specified by the Purchaser, certificates, registered in the name of the Purchaser or its designees, representing the shares of
Common Stock to which the Purchaser is entitled, without any restrictive legends and otherwise freely transferable on the books
and records of the Company.

c)                 
Filing Requirements. From the date of this Agreement until the Notes are no longer
outstanding, the Company will timely and voluntarily comply with all reporting requirements that are applicable to an issuer with
a class of shares registered pursuant to Section 12(g) of the 1934 Act, whether or not the Company is then subject to such reporting
requirements, and comply with all requirements related to any registration statement filed pursuant to this Agreement. The Company
will use reasonable efforts not to take any action or file any document (whether or not permitted by the 1933 Act or the 1934 Act
or the rules thereunder) to terminate or suspend such registration or to terminate or suspend its reporting and filing obligations
under said acts until the Notes are no longer outstanding. The Company will maintain the quotation or listing of its Common Stock
on the OTCQX, OTCQB, OTC Pink, New York Stock Exchange, NASDAQ Stock Market, NYSE MKT, f/k/a American Stock Exchange, or other
applicable principal trading exchange or market for the Common Stock (whichever of the foregoing is at the time the principal trading
exchange or market for the Common Stock) (the “Principal Market”), and will comply in all respects with the
Company’s reporting, filing and other obligations under the bylaws or rules of the Principal Market, as applicable. The Company
will provide Purchaser with copies of all notices it receives notifying the Company of the threatened and actual delisting of the
Common Stock from any Principal Market.  As of the date of this Agreement and the Closing Date, the OTCQB is the Principal
Market. Until the Note is no longer outstanding, the Company will continue the listing or quotation of the Common Stock on a Principal
Market and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules
of the Principal Market.

d)                 
Fees and Expenses. On or prior to the Closing, the Company shall pay or reimburse to
Purchaser a non-refundable, non-accountable sum equal to $7,250.00 for the fees, costs and expenses (including without limitation
due diligence and administrative expenses) incurred by the Purchaser in connection with the Purchaser’s due diligence and
negotiation of

    	16 

    	 

    

the Transaction Documents
and consummation of the Transactions. The Purchaser may withhold and offset the balance of such amount from the payment of its
Purchase Price otherwise payable hereunder at Closing, which offset shall constitute partial payment of such Purchase Price in
an amount equal to such offset. Except as expressly set forth in this Agreement, the Note, or the Disbursement Authorization to
the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all
other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement.
The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of
any Securities to the Purchaser. The Disbursement Authorization includes a disbursement of $2,750.00 to Purchaser’s legal
counsel for the Purchaser’s legal fees.

 

e)                 
Usury. To the extent it may lawfully do so, the Company hereby agrees not to insist
upon or plead or in any manner whatsoever claim, and will resist any and all efforts to be compelled to take the benefit or advantage
of, usury laws wherever enacted, now or at any time hereafter in force, in connection with any claim, action or proceeding that
may be brought by the Purchaser in order to enforce any right or remedy under the Note. Notwithstanding any provision to the contrary
contained in herein or under the Note, it is expressly agreed and provided that the total liability of the Company under the Note
for payments in the nature of interest shall not exceed the maximum lawful rate authorized under applicable law (the “Maximum
Rate”), and, without limiting the foregoing, in no event shall any rate of interest or default interest, or both of them,
when aggregated with any other sums in the nature of interest that the Company may be obligated to pay under the Note or herein
exceed such Maximum Rate. It is agreed that if the maximum contract rate of interest allowed by law and applicable to the Note
is increased or decreased by statute or any official governmental action subsequent to the date hereof, the new maximum contract
rate of interest allowed by law will be the Maximum Rate applicable to the Note from the effective date forward, unless such application
is precluded by applicable law. If under any circumstances whatsoever, interest in excess of the Maximum Rate is paid by the Company
to the Purchaser with respect to indebtedness evidenced by the Note, such excess shall be applied by the Purchaser to the unpaid
principal balance of any such indebtedness or be refunded to the Company, the manner of handling such excess to be at the Purchaser’s
election.

 

f)                  
Headings. The headings of this Agreement are for convenience of reference only and
shall not form part of, or affect the interpretation of, this Agreement.

g)                 
Severability. In the event that any provision of this Agreement is invalid or unenforceable
under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict
therewith and shall be deemed modified to conform with such statute or rule of law. Any provision hereof which may prove invalid
or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

h)                 
Entire Agreement; Amendments. This Agreement and the instruments referenced herein
contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically
set forth herein or therein, neither the Company nor the Purchaser makes any representation, warranty, covenant or undertaking
with

    	17 

    	 

    

respect to such matters.
No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the Purchaser.

i)                  
Notices. All notices, demands, requests, consents, approvals, and other communications
required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be: (i) personally served, (ii)
deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier
service with charges prepaid, or (iv) transmitted by hand delivery, telegram, email or facsimile, addressed as set forth below
or to such other address as such party shall have specified most recently by written notice. Any notice or other communication
required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by email or facsimile
with accurate confirmation generated by the transmitting facsimile machine or computer, at the address, email address or facsimile
number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the
first business day following such delivery (if delivered other than on a business day during normal business hours where such notice
is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed
to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall
be: 

Purchaser:EMA Financial,
LLC

40 Wall Street, 17th Floor

New York, NY 10005

Attn: Felicia Preston

Email: admin@emafin.com

 

Company: TPT Global Tech, Inc.

 

501 West Broadway, Suite 800

San Diego, CA 92101

Attn: Stephen J. Thomas, III,
Chief Executive Officer

Email: investr@tptglobaltech.com

 

Each
party shall provide notice to the other party of any change in address.

 

j)                  
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit
of the parties and their successors and assigns. Neither the Company nor the Purchaser shall assign this Agreement or any rights
or obligations hereunder without the prior written consent of the other. Notwithstanding the foregoing, subject to Section 2(f),
the Purchaser may assign its rights hereunder to any person that purchases Securities in a private transaction from the Purchaser
or to any of its “affiliates,” as that term is defined under the 1934 Act, without the consent of the Company.

k)                 
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties
hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced
by, any other person.

    	18 

    	 

    

l)                  
Survival. The representations and warranties of the Company and the agreements and
covenants set forth in this Agreement shall survive the Closing hereunder notwithstanding any due diligence investigation conducted
by or on behalf of the Purchaser. The Company agrees to indemnify and hold harmless the Purchaser and all their officers, directors,
employees and agents for loss or damage arising as a result of or related to any breach or alleged breach by the Purchaser of any
of its representations, warranties and covenants set forth in this Agreement or any of its covenants and obligations under this
Agreement, including advancement of expenses as they are incurred.

m)              
Further Assurances. Each party shall do and perform, or cause to be done and performed,
all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents,
as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the
consummation of the transactions contemplated hereby.

n)                 
No Strict Construction. The language used in this Agreement will be deemed to be the
language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any
party.

o)                 
Remedies. The Company acknowledges that a breach by it of its obligations hereunder
will cause irreparable harm to the Purchaser by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly,
the Company acknowledges that the remedy at law for a breach of its obligations under this Agreement will be inadequate and agrees,
in the event of a breach or threatened breach by the Company of the provisions of this Agreement, that the Purchaser shall be entitled,
in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction
or injunctions restraining, preventing or curing any breach of this Agreement and to enforce specifically the terms and provisions
hereof, without the necessity of showing economic loss and without any bond or other security being required.

p)                 
Counterparts. This Agreement may be executed in any number of counterparts, each of
which when so executed and delivered shall be deemed to be an original and all of which together shall be deemed to be one and
the same agreement. Any signature transmitted by facsimile, e-mail, or other electronic means shall be deemed to be an original
signature.

 

 

[signature page to follow]

    	19 

    	 

    

 

 

IN WITNESS
WHEREOF, the undersigned Purchaser and the Company have caused this Agreement to be duly executed as of the date first above written.

TPT GLOBAL TECH, INC.

 

	By:	 	 
	Name:	Stephen J. Thomas, III	 
	Title:	Chief Executive Officer	 

 

 

EMA FINANCIAL, LLC

 

	By:	/s/
    Felicia Preston	 
	Name:	Felicia Preston	 
	Title:	Director	 

 

    	20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]